Auranofin suppresses plasminogen activator inhibitor-2 expression through annexin A5 induction in human prostate cancer cells

Biomolecules and Therapeutics

Volumn 25, Issue 2, 2017, Pages 177-185

  Shin, Dong Won ^a   Kwon, Yeo Jung ^a   Ye, Dong Jin ^a   Baek, Hyoung Seok ^a   Lee, Joo Eun ^a   Chun, Young Jin ^a  

^a Chung Ang University   (South Korea)

Author keywords

Annexin A5; Apoptosis; Auranofin; Plasminogen activator inhibitor 2

Indexed keywords

AURANOFIN; LIPOCORTIN 5; PLASMINOGEN ACTIVATOR INHIBITOR 2; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; PAI 2 GENE; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 85015827685     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2016.223     Document Type: Article

References (39)

1. Boersma, HH, Kietselaer, BL, Stolk, LM, Bennaghmouch, A, Hofstra, L, Narula, J, Heidendal, GA, and Reutelingsperger, CP (2005). Past, present, and future of annexin A5: from protein discovery to clinical applications. J Nucl Med. 46, 2035-2050.
2. Bohn, H, and Kraus, W (1979). Isolation and characterization of a new placenta specific protein (PP10) (author’s transl). Arch Gynecol. 227, 125-134.
3. Bolstad, BM, Irizarry, RA, Astrand, M, and Speed, TP (2003). A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19, 185-193.
4. Cardó-Vila, M, Arap, W, and Pasqualini, R (2003). ανβ5 integrin-dependent programmed cell death triggered by a peptide mimic of annexin V. Mol. Cell. 11, 1151-1162.
5. Clinicaltrials.gov (2016) Phase I and II study of auranofin in chronic lymphocytic leukemia (CLL).Available from: https://clinicaltrials.gov/ct2/show/NCT01419691/.
6. Croucher, DR, Saunders, DN, Lobov, S, and Ranson, M (2008). Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat. Rev. Cancer. 8, 535-545.
7. Demange, P, Voges, D, Benz, J, Liemann, S, Göttig, P, Berendes, R, Burger, A, and Huber, R (1994). Annexin V: the key to understanding ion selectivity and voltage regulation?. Trends Biochem Sci. 19, 272-276.
8. Dickinson, JL, Bates, EJ, Ferrante, A, and Antalis, TM (1995). Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor α-induced apoptosis. J Biol Chem. 270, 27894-27904.
9. Eisen, MB, Spellman, PT, Brown, PO, and Botstein, D (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 95, 14863-14868.
10. Ganesh, S, Sier, CF, Griffioen, G, Vloedgraven, HJ, de Boer, A, Welvaart, K, van de Velde, CJ, van Krieken, JH, Verheijen, JH, Lamers, CBHW, and Verspaget, HW (1994). Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 54, 4065-4071.
11. Han, S, Kim, K, Kim, H, Kwon, J, Lee, YH, Lee, CK, Song, Y, Lee, SJ, Ha, N, and Kim, K (2008). Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages. Arch Pharm Res. 31, 67-74.
12. Hong, M, Park, N, and Chun, YJ (2014). Role of annexin a5 on mitochondria-dependent apoptosis induced by tetramethoxystilbene in human breast cancer cells. Biomol. Ther. (Seoul). 22, 519-524.
13. Irizarry, RA, Hobbs, B, Collin, F, Beazer-Barclay, YD, Antonellis, KJ, Scherf, U, and Speed, TP (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4, 249-264.
14. Irving, JA, Pike, RN, Lesk, AM, and Whisstock, JC (2000). Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res. 10, 1845-1864.
15. Jeon, KI, Jeong, JY, and Jue, DM (2000). Thiol-reactive metal compounds inhibit NF-κB activation by blocking IκB kinase. J Immunol. 164, 5981-5989.
16. Jeong, JJ, Park, N, Kwon, YJ, Ye, DJ, Moon, A, and Chun, YJ (2014). Role of annexin A5 in cisplatin-induced toxicity in renal cells: molecular mechanism of apoptosis. J Biol Chem. 289, 2469-2481.
17. Jing, J, Chen, L, Fu, HY, Fan, K, Yao, Q, Ge, YF, Lu, JC, and Yao, B (2015). Annexin V-induced rat Leydig cell proliferation involves Ect2 via RhoA/ROCK signaling pathway. Sci Rep. 5, 9437.
18. Kean, WF, Hart, L, and Buchanan, WW (1997). Auranofin. Br J Rheumatol. 36, 560-572.
19. Kim, NH, Lee, MY, Park, SJ, Choi, JS, Oh, MK, and Kim, IS (2007). Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology. 122, 607-614.
20. Koopman, G, Reutelingsperger, CP, Kuijten, GA, Keehnen, RM, Pals, ST, and van Oers, MH (1994). Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84, 1415-1420.
21. Kruithof, EK, Baker, MS, and Bunn, CL (1995). Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood. 86, 4007-4024.
22. Kumar, S, and Baglioni, C (1991). Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem. 266, 20960-20964.
23. Kwon, YJ, Jung, JJ, Park, NH, Ye, DJ, Kim, D, Moon, A, and Chun, YJ (2013). Annexin A5 as a new potential biomarker for cisplatin-induced toxicity in human kidney epithelial cells. Biomol. Ther. (Seoul). 21, 190-195.
24. Li, H, Hu, J, Wu, S, Wang, L, Cao, X, Zhang, X, Dai, B, Cao, M, Shao, R, Zhang, R, Majidi, M, Ji, L, Heymach, JV, Wang, M, Pan, S, Minna, J, Mehran, RJ, Swisher, SG, Roth, JA, and Fang, B (2016). Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. 7, 3548-3558.
25. Liu, N, Li, X, Huang, H, Zhao, C, Liao, S, Yang, C, Liu, S, Song, W, Lu, X, Lan, X, Chen, X, Yi, S, Xu, L, Jiang, L, Zhao, C, Dong, X, Zhou, P, Li, S, Wang, S, Shi, X, Dou, PQ, Wang, X, and Liu, J (2014). Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget. 5, 5453-5471.
26. Mahoney, CW, Hensey, CE, and Azzi, A (1989). Auranofin, gold thiomalate, and gold thioglucose inhibit protein kinase C. Biochem Pharmacol. 38, 3383-3386.
27. Marzano, C, Gandin, V, Folda, A, Scutari, G, Bindoli, A, and Rigobello, MP (2007). Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med. 42, 872-881.
28. Medcalf, RL, and Stasinopoulos, SJ (2005). The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. FEBS J. 272, 4858-4867.
29. Nakaya, A, Sagawa, M, Muto, A, Uchida, H, Ikeda, Y, and Kizaki, M (2011). The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity. Leuk Res. 35, 243-249.
30. Nordengren, J, Fredstorp Lidebring, M, Bendahl, PO, Brünner, N, Fernö, M, Högberg, T, Stephens, RW, Wilén, R, and Casslén, B (2002). High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int. J. Cancer. 97, 379-385.
31. Park, N, and Chun, YJ (2014). Auranofin promotes mitochondrial apoptosis by inducing annexin A5 expression and translocation in human prostate cancer cells. J. Toxicol. Environ. Health Part A. 77, 1467-1476.
32. Park, SH, Lee, JH, Berek, JS, and Hu, MC (2014). Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. Int J Oncol. 45, 1691-1698.
33. Reutelingsperger, CP, Hornstra, G, and Hemker, HC (1985). Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem. 151, 625-629.
34. Rothhut, B, Dubois, T, Feliers, D, Russo-Marie, F, and Oudinet, JP (1995). Inhibitory effect of annexin V on protein kinase C activity in mesangial cell lysates. Eur J Biochem. 232, 865-872.
35. Silverman, GA, Jockel, JI, Domer, PH, Mohr, RM, Taillon-Miller, P, and Korsmeyer, SJ (1991). Yeast artificial chromosome cloning of a two-megabase-size contig within chromosomal band 18q21 establishes physical linkage between BCL2 and plasminogen activator inhibitor type-2. Genomics. 9, 219-228.
36. Stern, I, Wataha, JC, Lewis, JB, Messer, RLW, Lockwood, PE, and Tseng, WY (2005). Anti-rheumatic gold compounds as sub-lethal modulators of monocytic LPS-induced cytokine secretion. Toxicol. In Vitro. 19, 365-371.
37. Stringer, B, Udofa, EA, and Antalis, TM (2012). Regulation of the human plasminogen activator inhibitor type 2 gene: cooperation of an upstream silencer and transactivator. J Biol Chem. 287, 10579-10589.
38. Vermes, I, Haanen, C, Steffens-Nakken, H, and Reutelingsperger, C (1995). A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods. 184, 39-51.
39. Zhou, HM, Bolon, I, Nichols, A, Wohlwend, A, and Vassalli, JD (2001). Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. Cancer Res. 61, 970-976.